TrialDiabetes, obesity & metabolism2013

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

E Ferrannini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.